142 related articles for article (PubMed ID: 17826523)
1. Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.
Park JY; Tanner JP; Sellers TA; Huang Y; Stevens CK; Dossett N; Shankar RA; Zachariah B; Heysek R; Pow-Sang J
Urology; 2007 Aug; 70(2):374-9. PubMed ID: 17826523
[TBL] [Abstract][Full Text] [Related]
2. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.
Park J; Chen L; Ratnashinge L; Sellers TA; Tanner JP; Lee JH; Dossett N; Lang N; Kadlubar FF; Ambrosone CB; Zachariah B; Heysek RV; Patterson S; Pow-Sang J
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1473-8. PubMed ID: 16896035
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer.
Setlur SR; Chen CX; Hossain RR; Ha JS; Van Doren VE; Stenzel B; Steiner E; Oldridge D; Kitabayashi N; Banerjee S; Chen JY; Schäfer G; Horninger W; Lee C; Rubin MA; Klocker H; Demichelis F
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):229-39. PubMed ID: 20056642
[TBL] [Abstract][Full Text] [Related]
4. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.
Hu DG; Gardner-Stephen D; Severi G; Gregory PA; Treloar J; Giles GG; English DR; Hopper JL; Tilley WD; Mackenzie PI
Mol Pharmacol; 2010 Oct; 78(4):714-22. PubMed ID: 20628005
[TBL] [Abstract][Full Text] [Related]
5. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
[TBL] [Abstract][Full Text] [Related]
6. The UGT2B17 gene deletion is not associated with prostate cancer risk.
Olsson M; Lindström S; Häggkvist B; Adami HO; Bälter K; Stattin P; Ask B; Rane A; Ekström L; Grönberg H
Prostate; 2008 Apr; 68(5):571-5. PubMed ID: 18247404
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis.
Cai L; Huang W; Chou KC
Protein Pept Lett; 2012 Jan; 19(1):62-9. PubMed ID: 21919858
[TBL] [Abstract][Full Text] [Related]
8. Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate.
Karypidis AH; Olsson M; Andersson SO; Rane A; Ekström L
Pharmacogenomics J; 2008 Apr; 8(2):147-51. PubMed ID: 17387331
[TBL] [Abstract][Full Text] [Related]
9. The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case-control study in Caucasians.
Gallagher CJ; Kadlubar FF; Muscat JE; Ambrosone CB; Lang NP; Lazarus P
Cancer Detect Prev; 2007; 31(4):310-5. PubMed ID: 17935910
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.
Pâquet S; Fazli L; Grosse L; Verreault M; Têtu B; Rennie PS; Bélanger A; Barbier O
J Clin Endocrinol Metab; 2012 Mar; 97(3):E428-32. PubMed ID: 22170718
[TBL] [Abstract][Full Text] [Related]
11. Association of uridine diphosphate-glucuronosyltransferase 2B gene variants with serum glucuronide levels and prostate cancer risk.
Grant DJ; Hoyo C; Oliver SD; Gerber L; Shuler K; Calloway E; Gaines AR; McPhail M; Livingston JN; Richardson RM; Schildkraut JM; Freedland SJ
Genet Test Mol Biomarkers; 2013 Jan; 17(1):3-9. PubMed ID: 23098242
[TBL] [Abstract][Full Text] [Related]
12. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility.
Chang BL; Zheng SL; Hawkins GA; Isaacs SD; Wiley KE; Turner A; Carpten JD; Bleecker ER; Walsh PC; Trent JM; Meyers DA; Isaacs WB; Xu J
Cancer Res; 2002 Mar; 62(6):1784-9. PubMed ID: 11912155
[TBL] [Abstract][Full Text] [Related]
13. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
[TBL] [Abstract][Full Text] [Related]
14. UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.
Grant DJ; Chen Z; Howard LE; Wiggins E; De Hoedt A; Vidal AC; Carney ST; Squires J; Magyar CE; Huang J; Freedland SJ
BMC Cancer; 2017 Jul; 17(1):463. PubMed ID: 28673330
[TBL] [Abstract][Full Text] [Related]
15. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
[TBL] [Abstract][Full Text] [Related]
16. Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk.
Amrousy YM; Haffez H; Abdou DM; Atya HB
Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35795973
[TBL] [Abstract][Full Text] [Related]
17. Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer.
Park J; Chen L; Shade K; Lazarus P; Seigne J; Patterson S; Helal M; Pow-Sang J
J Urol; 2004 Jun; 171(6 Pt 1):2484-8. PubMed ID: 15126881
[TBL] [Abstract][Full Text] [Related]
18. UDP-glucuronosyltransferase 2B17 genotype and the risk of lung cancer among Austrian Caucasians.
Gruber M; Le T; Filipits M; Gsur A; Mannhalter C; Jäger U; Vanura K
Cancer Epidemiol; 2013 Oct; 37(5):625-8. PubMed ID: 23850147
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.
Wijayakumara DD; Hu DG; Meech R; McKinnon RA; Mackenzie PI
J Pharmacol Exp Ther; 2015 Sep; 354(3):417-25. PubMed ID: 26163549
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer.
Cunningham JM; Hebbring SJ; McDonnell SK; Cicek MS; Christensen GB; Wang L; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):969-78. PubMed ID: 17507624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
